You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

 

Online download statistics by month:

Online download statistics by month: June 2023 to February 2026

AbstractFullPdf
Jun 2023732741176
Jul 202330430544
Aug 202335935949
Sep 202318218257
Oct 202315515541
Nov 202324024169
Dec 202317017264
Jan 202416917392
Feb 202414914951
Mar 2024183183121
Apr 2024173173113
May 202414514665
Jun 202415315360
Jul 202416016275
Aug 2024134135197
Sep 202410310261
Oct 202412913069
Nov 202410911170
Dec 202416917371
Jan 202517617786
Feb 202515115179
Mar 202516416482
Apr 202520520672
May 202521321479
Jun 202514914965
Jul 2025110
Aug 2025110
Feb 2026110
Total497950092008